The efficacy was evaluated by positive and negative symptom scale(PANSS), and the side effects by treatment emergent symptom scale(TESS).
以阳性和阴性症状量表（PANSS）评定临床疗效，以副反应量表（TESS）评定不良反应。
Hamilton depression rating scale (HAMD), clinical general impressional scale (CGI) and treatment emergent symptom scale (TESS) were assessed.
采用汉密尔顿抑郁量表(HAMD)、临床疗效总评量表(CGI)、副反应量表(TESS)评定疗效及不良反应。
Positive and negative symptom scale (PANSS) and treatment emergent symptom scale (TESS) were used to evaluate the efficacy and side effects respectively.
用阳性与阴性症状量表(PANSS)和副反应量表(TESS)评定疗效和不良反应。
The positive and negative symptom scale (PANSS) is adopted to appraise the curative effect, and the treatment emergent symptom scale (TESS) is adopted to appraise by-reaction.
采用阳性症状量表和阴性症状量表(PANSS)以评定齐拉西酮对女性精神分裂症的疗效，采用不良反应量表(TESS)评定该药物的副反应。
The brief psychiatric rating scale (BPRS) was used to evaluate the effect, treatment emergent symptom scale (TESS) to evaluate side effects, and all the patients were followed up for 2 years.
用简明精神症状量表(BPRS)和药物副反应量表(TESS)评定疗效和副反应，治疗结束后随访两年。
The efficiency and side effects were assessed with the postive and negative symptom scale (PANSS)and treatment emergent symptom seale (TESS) before and 4,8and 12 weekends after the treatment.
在治疗前，治疗后4、8和12周末分别以阻性症状和阴性症状量表（PANSS）和副反应量表（TESS）评定疗效和副作用。
The efficiency and side effects were assessed with the postive and negative symptom scale (PANSS)and treatment emergent symptom seale (TESS) before and 4,8and 12 weekends after the treatment.
在治疗前，治疗后4、8和12周末分别以阻性症状和阴性症状量表（PANSS）和副反应量表（TESS）评定疗效和副作用。
应用推荐